Results 161 to 170 of about 52,090 (308)

cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers

open access: yesNature, 2022
Christy Hong   +16 more
semanticscholar   +1 more source

CgA [PDF]

open access: yes, 2019
openaire   +1 more source

Sustained‐Release Ulcer‐Protective Microarray Patch With Dihydrocapsaicin for Diabetic Wound Regeneration

open access: yesExploration, EarlyView.
Schematic illustration of the effect of microneedles incorporating cerium‐based MOF loading dihydrocapsaicin (MN‐MOF@DHC) to scavenge reactive oxygen species (ROS) generation, beanti‐inflammatory, inhibit the apoptosis of endothelial cells (ECs), promote angiogenesis, and accelerate diabetic wound healing. ABSTRACT Diabetic foot ulcers (DFUs) present a
Yuxu Wu   +11 more
wiley   +1 more source

SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma. [PDF]

open access: yesCancer Res
Uprety A   +10 more
europepmc   +1 more source

Exploring the Effects of Frailty and Sarcopenia on Dysphagia in Head and Neck Cancer: A Scoping Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Frailty and sarcopenia may influence head and neck cancer (HNC) treatment outcomes, including dysphagia. Current understanding of this relationship, however, remains limited. This scoping review aimed to synthesize existing evidence on the relationship between frailty and/or sarcopenia and dysphagia in adults with HNC.
Rishni Perera   +4 more
wiley   +1 more source

Barrier-to-autointegration factor protects against the cGAS-STING response to chromatin bridges. [PDF]

open access: yesPLoS Genet
Chastant L   +4 more
europepmc   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

open access: yesInternational Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang   +10 more
wiley   +1 more source

Advances in Immunological Combination Therapy for Colorectal Cancer

open access: yesiMetaMed, EarlyView.
Review the progress of combined immunotherapy for colorectal cancer. ABSTRACT Immune checkpoint inhibitors (ICIs) have been utilized extensively and shown to be therapeutically beneficial in the treatment of solid tumors in recent years. Nonetheless, considerable heterogeneity in Colorectal cancer (CRC) requires careful consideration.
Jiayue Wu   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy